NCT03172624View on ClinicalTrials.gov

Study of Nivolumab Plus Ipilimumab in Patients With Salivary Gland Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

64

Participants

Timeline

Start Date

May 26, 2017

Primary Completion Date

December 18, 2024

Study Completion Date

December 18, 2024

Conditions
Salivary Gland Cancer
Interventions
DRUG

Nivolumab

nivolumab 3 mg/kg every 2 weeks

DRUG

Ipilimumab

ipilimumab 1 mg/kg every 6 weeks (1 cycle= 6 weeks)

Trial Locations (8)

10065

Memorial Sloan Kettering Cancer Center, New York

10604

Memorial Sloan Kettering Westchester, Harrison

11553

Memorial Sloan Kettering Nassau, Uniondale

11570

Memorial Sloan Kettering Rockville Centre, Rockville Centre

11725

Memorial Sloan Kettering Commack, Commack

07920

Memorial Sloan Kettering Basking Ridge, Basking Ridge

07748

Memorial Sloan Kettering Monmouth, Middletown

07645

Memorial Sloan Kettering Bergen, Montvale

Sponsors

Collaborators (1)

Bristol-Myers Squibb
All Listed Sponsors
collaborator

Bristol-Myers Squibb

INDUSTRY

lead

Memorial Sloan Kettering Cancer Center

OTHER